Program
Docetaxel
Also written as “docetaxel”, “Taxotere” and “HB1801”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.
Drug pageDocetaxel: every studyMany companies study it; this page follows only the 142 they lead. All 1,164 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 540 open or running | phase 4since Jan 18, 2006 | Nov 1, 1999 | none ahead |
| Hoffmann-La Roche | 220 open or running | phase 4since Aug 5, 2005 | Feb 12, 2004 | none ahead |
| CSPC Pharmaceutical Groupits history only | 1511 open or running | phase 3since Apr 20, 2023 | Mar 10, 2021 | Dec 16, 2026phase 3 · NCT06747338 |
| Eli Lillyits history only | 81 open or running | phase 3since Nov 1, 2004 | Nov 1, 2004 | May 2027phase 2 · NCT05999994 |
| Pfizerits history only | 70 open or running | phase 2since Jan 4, 2002 | Jan 4, 2002 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 2since Jul 17, 2003 | Jul 17, 2003 | none ahead |
| Amgenits history only | 40 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Merckits history only | 30 open or running | phase 2since Oct 4, 2007 | Oct 4, 2007 | none ahead |
| Novaceaits history only | 30 open or running | phase 3since Aug 9, 2002 | Aug 9, 2002 | none ahead |
| Novartisits history only | 20 open or running | phase 3since Jun 29, 2004 | Jun 29, 2004 | none ahead |
| Samyang Biopharmaceuticalsits history only | 20 open or running | phase 1since Mar 21, 2011 | Mar 21, 2011 | none ahead |
| Academy Military Medical Science, Chinaits history only | 10 open or running | phase 2since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 1since Nov 23, 2009 | Nov 23, 2009 | none ahead |
| HealthCare Global Enterpriseits history only | 10 open or running | phase 2since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Hope Cancer Instituteits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Ionis Pharmaceuticalsits history only | 10 open or running | phase 2since Nov 2, 2010 | Nov 2, 2010 | none ahead |
| Lidds ABits history only | 10 open or running | phase 1since Mar 18, 2021 | Mar 18, 2021 | none ahead |
| NanOlogyits history only | 10 open or running | phase 1since Feb 5, 2020 | Feb 5, 2020 | none ahead |
| Oshadi Drug Administrationits history only | 10 open or running | phase 2since May 7, 2014 | May 7, 2014 | none ahead |
| Relmada Therapeuticsits history only | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| Shanghai Miracogenits history only | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Simcere Pharmaceutical Groupits history only | 10 open or running | phase 1since May 25, 2020 | May 25, 2020 | none ahead |
| Sumitomo Pharmaits history only | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
| Swedish Orphan Biovitrumits history only | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| Zhuhai Beihai Biotechits history only | 11 open or running | phase 2since Dec 9, 2024 | Dec 9, 2024 | none ahead |
| Zivenaits history only | 10 open or running | phase 2since May 11, 2004 | May 11, 2004 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Clovis Oncology, Astellas Pharma, Exelixis, Gilead Sciences, iTeos Belgium, Intas Pharmaceuticals, Lambda Therapeutic Research, Medigen Biotechnology, US Biotest, Quintiles, MDS Pharma Services, AstraZeneca and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Feb 12, 2004.
- Feb 17, 2009Phase 2 study in Breast NeoplasmsNCT00845910 · 22 enrolled · Taiwan
- Jun 24, 2009Phase 1 study in Solid CancersNCT00927589 · 59 enrolled · United States
- Jul 6, 2009Phase 2 study in Breast NeoplasmsNCT00934856 · 98 enrolled · United States, France, Spain and more
- Aug 21, 2009Phase 2 study in Breast NeoplasmsNCT00964704
- May 22, 2013Phase 1 study in Breast NeoplasmsNCT01862081 · 80 enrolled · United States, Belgium, Canada and more
- Dec 4, 2013Phase 2 study in Breast NeoplasmsNCT02005549 · 18 enrolled · Austria
- Mar 23, 2015Phase 4 study in Breast NeoplasmsNCT02419742 · 110 enrolled · India
- Mar 23, 2015Phase 3 study in Breast NeoplasmsNCT02402712 · 418 enrolled · Belgium, Bulgaria, Canada and more
- May 13, 2015Phase 4 study in Breast NeoplasmsNCT02445586 · 52 enrolled · India
- Nov 12, 2015Phase 1 study in Breast NeoplasmsNCT02605915 · 98 enrolled · United States
- Apr 20, 2016Phase 2 study in Breast NeoplasmsNCT02748213 · 225 enrolled · Australia, Brazil, Canada and more
- Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03337698 · 314 enrolled · United States, Australia, France and more
- May 15, 2020Phase 1 study in Prostatic Neoplasms, Castration-ResistantNCT04404140 · 6 enrolled · France, Italy, Spain and more
- Jul 7, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04471428 · 366 enrolled · United States, Australia, Austria and more
TargetBeta
“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 202 |
| cabazitaxelrule | Sanofi | phase 4 | 21 |
| Vinblastinerule | Takeda | phase 4 | 4 |
| desoxyepothilone Brule | beijing-biostar-pharmaceuticals-co-ltd | phase 3 | 19 |
| plinabulinrule | beyondspring-pharmaceuticals-inc | phase 3 | 8 |
Studies
All 22 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04471428Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Completed | Sep 28, 2022 | 366 |
| NCT04404140Prostatic Neoplasms, Castration-Resistant · France, Italy, Spain and more | 1 | Terminated | Oct 14, 2022 | 6 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Oct 14, 2025 | 314 |
| NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more | 2 | Completed | Mar 2006 | 225 |
| NCT02605915Breast Neoplasms · United States | 1 | Completed | Nov 13, 2019 | 98 |
| NCT02445586Breast Neoplasms · India | 4 | Completed | Sep 26, 2018 | 52 |
| NCT02419742Breast Neoplasms · India | 4 | Completed | Jun 24, 2021 | 110 |
| NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more | 3 | Completed | Feb 22, 2019 | 418 |
| NCT02005549Breast Neoplasms · Austria | 2 | Completed | Apr 2008 | 18 |
| NCT01862081Breast Neoplasms · United States, Belgium, Canada and more | 1 | Completed | Jun 9, 2017 | 80 |
| NCT00964704Breast Neoplasms | 2 | Withdrawn | Aug 2013 | 0 |
| NCT00934856Breast Neoplasms · United States, France, Spain and more | 2 | Completed | Oct 2013 | 98 |
| NCT00927589Solid Cancers · United States | 1 | Completed | Feb 2013 | 59 |
| NCT00845910Breast Neoplasms · Taiwan | 2 | Terminated | May 2011 | 22 |
| NCT00774241Breast Neoplasms | 4 | Withdrawn | Nov 2013 | 0 |
| NCT00773695Breast Neoplasms · Norway | 2 | Completed | Nov 9, 2022 | 150 |
| NCT00661778Carcinoma, Non-Small-Cell Lung · Spain | 2 | Completed | Jul 2011 | 50 |
| NCT00576901Breast Neoplasms · Spain | 2 | Terminated | Jun 2009 | 23 |
| NCT00559754Breast Neoplasms · Spain | 2 | Completed | Sep 2010 | 72 |
| NCT00545688Breast Neoplasms · Australia, Austria, Brazil and more | 2 | Completed | Sep 22, 2014 | 417 |
| NCT00127933Breast Neoplasms · United States | 4 | Completed | Apr 2009 | 157 |
| NCT00077857Breast Neoplasms · United States, Bosnia and Herzegovina, China and more | 2 | Completed | Mar 2010 | 470 |
How it is read
Names in the registry
- “Docetaxel”, 93 entries
- “docetaxel”, 37 entries
- “Taxotere”, 9 entries
- “HB1801”, 8 entries
- “Docetaxel for injection (Albumin-bound)”, 4 entries
Codes read as this program: CKD810.
Conditions, from the studies’ own filings
- Breast Neoplasms, 54 studies
- Carcinoma, Non-Small-Cell Lung, 48 studies
- Prostatic Neoplasms, 21 studies
- Stomach Neoplasms, 9 studies
- Lung Neoplasms, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.